ArticleProceedings of the National Academy of Sciences of the United States of America2025
Improving the efficacy of anti-SSEA4 antibody in pancreatic cancer immunotherapy with glyco-optimization and immune checkpoint blockade.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selective fluorination of Fc glycans enhances antibody-mediated effector functions.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pancreatic cancer remains one of the most lethal malignancies with limited therapeutic options. Among the alternative targets explored for pancreatic cancer, the glycolipid stage-specific embryonic antigen-4 (SSEA4) has been extensively studied. We have previously demonstrated that the chimeric anti-SSEA4 antibody with alpha-2,6-sialylated complex type biantennary glycan (SCT) or its 3-fluorosialyl derivative (FSCT) attached to the Fc-Asn297 residue exhibited enhanced binding to the Fc-receptors FcγRIIIA and FcγRIIA which are responsible for antibody-dependent cellular cytotoxicity and phagocytosis as well as vaccinal effect. Here, we found that high-SSEA4 expression correlates with increasing tumor proliferation and sensitivity to the glyco-optimized antibodies (anti-SSEA4-SCT and anti-SSEA4-FSCT) which preferentially recruit NKG2D-expressing natural killer cells and FcγRIIA-bearing macrophages with enhanced target killing activity. We also uncovered an immune evasion mechanism involving the interaction of sialoglycans on the cancer cell with Siglec-9 on NK cells or Siglec-10 on macrophages to block the antibody-mediated effector functions, and this immune checkpoint inhibition can be suppressed with the removal of sialic acid on cancer cells or blockade of Siglec recognition. In xenograft models, the glyco-optimized antibodies exhibited superior inhibition of tumor growth with high-SSEA4 expression compared to the wild-type antibody and persistent antitumor activity without additional antibody administration. These findings support anti-SSEA4 antibodies with enhanced effector functions and blockade of Siglec-mediated immune checkpoint as a promising therapeutic strategy for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.